Evidence map›Paper›PMID 38358310›Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2024

In Vivo Stimulation of Therapeutic Antigen-Specific T Cells in an Artificial Lymph Node Matrix.

Natalie K Livingston, John W Hickey, Hajin Sim, Sebastian F Salathe, Joseph Choy, Jiayuan Kong, Aliyah B Silver, Jessica L Stelzel, Mary O Omotoso, Shuyi Li and 12 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Antigen-conjugated scaffolds enable sustained delivery of antigen and enrichment of antigen-specific T-cells.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  6. Oral immunization withJournal for immunotherapy of cancer · 2026
    Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Engineering immune organoids to regenerate host immune system.Current opinion in genetics & development · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 1 country.

Natalie K LivingstonDepartment of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, 21205, USA.ORCID https://orcid.org/0000-0002-0909-9284
John W HickeyDepartment of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, 21205, USA.
Hajin SimDepartment of Pathology, School of Medicine, Johns Hopkins University, Baltimore, MD, 21205, USA.
Sebastian F SalatheDepartment of Biology, Krieger School of Arts and Sciences, Johns Hopkins University, Baltimore, MD, 21218, USA.
Joseph ChoyTranslational Tissue Engineering Center, Johns Hopkins University, Baltimore, MD, 21231, USA.
Jiayuan KongTranslational Tissue Engineering Center, Johns Hopkins University, Baltimore, MD, 21231, USA.
Aliyah B SilverTranslational Tissue Engineering Center, Johns Hopkins University, Baltimore, MD, 21231, USA.
Jessica L StelzelDepartment of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, 21205, USA.
Mary O OmotosoDepartment of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, 21205, USA.
Shuyi LiDepartment of Pathology, School of Medicine, Johns Hopkins University, Baltimore, MD, 21205, USA.
Worarat ChaisawangwongGraduate Program in Immunology, School of Medicine, Johns Hopkins University, Baltimore, MD, 21205, USA.
Sayantika RoyDepartment of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, 21205, USA.
Emily C AriailDepartment of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, 21205, USA.
Mara R LanisDepartment of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, 21205, USA.
Pratibha PradeepDepartment of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, 21205, USA.
Joan Glick BielerDepartment of Pathology, School of Medicine, Johns Hopkins University, Baltimore, MD, 21205, USA.
Savannah Est WitteDepartment of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, 21205, USA.
Elissa LeonardDepartment of Chemical and Biomolecular Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA.
Joshua C DoloffDepartment of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, 21205, USA.
Jamie B SpanglerDepartment of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, 21205, USA.
Hai-Quan MaoDepartment of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, 21205, USA.
Jonathan P SchneckDepartment of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, 21205, USA.ORCID https://orcid.org/0000-0001-5346-2776
Johns Hopkins University · USBloomberg (United States) · US

Funding

Training: Molecular & Cellular Bases of Infectious DiseasesT32AI007417 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Arturo Casadevall · 1994 to 2026
$11.9M
TR&D Project 3P41EB028239 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI Jamie Berta Spangler · 2019 to 2026
$11.5M
Biomimetic Matrix for Ex Vivo and In Vivo Activation of T CellsR01EB029341 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI MAO, HAI-QUAN, SCHNECK, JONATHAN P · 2020 to 2023
$1.9M
A high-throughput nanoparticle assay to characterize cancer neoepitope-specific T cellsR33CA229042 · NCI · JOHNS HOPKINS UNIVERSITY · PI SCHNECK, JONATHAN P · 2019 to 2021
$1.4M
Identification of cancer neoepitope-specific T cells using novel high-throughput hydrogel based platformsR33CA278429 · NCI · JOHNS HOPKINS UNIVERSITY · PI JONATHAN P SCHNECK · 2024 to 2026
$1.2M
Antigen-specific T cell Redirectors, ATR, for immunotherapyR21CA185819 · NCI · JOHNS HOPKINS UNIVERSITY · PI SCHNECK, JONATHAN P · 2015 to 2016
$388k
Artificial Immune Moduating (AIM??)Platform for the Treatment of CancerR43CA177009 · NCI · NEXIMMUNE, INC. · PI MCCREEDY, BRUCE J, SCHNECK, JONATHAN P · 2013 to 2013
$288k
Engineering injectable T cell stimulating microparticles for cancer immunotherapyF31CA275271 · NCI · JOHNS HOPKINS UNIVERSITY · PI LIVINGSTON, NATALIE KATERINA · 2022 to 2023
$81k
National Science Foundation DGE-1232825National Science Foundation DGE-2139757Natural Sciences and Engineering Research Council of Canada's PGSD3-557758-2021NCI NIH HHS F31 CA275271NCI NIH HHS R21 CA185819NCI NIH HHS R33 CA229042NCI NIH HHS R33 CA278429NCI NIH HHS R43 CA177009NIAID NIH HHS T32 AI007417NIBIB NIH HHS P41 EB028239NIBIB NIH HHS R01 EB029341NIH HHS F31CA275271NIH HHS P41EB028239NIH HHS R01EB029341NIH HHS R21CA185819
6 · The paper itself

Abstract

T cells are critical mediators of antigen-specific immune responses and are common targets for immunotherapy. Biomaterial scaffolds have previously been used to stimulate antigen-presenting cells to elicit antigen-specific immune responses; however, structural and molecular features that directly stimulate and expand naïve, endogenous, tumor-specific T cells in vivo have not been defined. Here, an artificial lymph node (aLN) matrix is created, which consists of an extracellular matrix hydrogel conjugated with peptide-loaded-MHC complex (Signal 1), the co-stimulatory signal anti-CD28 (Signal 2), and a tethered IL-2 (Signal 3), that can bypass challenges faced by other approaches to activate T cells in situ such as vaccines. This dynamic immune-stimulating platform enables direct, in vivo antigen-specific CD8+ T cell stimulation, as well as recruitment and coordination of host immune cells, providing an immuno-stimulatory microenvironment for antigen-specific T cell activation and expansion. Co-injecting the aLN with naïve, wild-type CD8+ T cells results in robust activation and expansion of tumor-targeted T cells that kill target cells and slow tumor growth in several distal tumor models. The aLN platform induces potent in vivo antigen-specific CD8+ T cell stimulation without the need for ex vivo priming or expansion and enables in situ manipulation of antigen-specific responses for immunotherapies.

Indexed as

CD8-Positive T-LymphocytesLymph NodesAnimalsCD28 AntigensCell Line, TumorExtracellular MatrixHumansHydrogelsImmunotherapyInterleukin-2Lymphocyte ActivationMiceMice, Inbred C57BLPeptidesCD28 AntigensHydrogelsInterleukin-2Peptidesadoptive T cell therapyartificial lymph nodecancerhydrogelimmunotherapyin vivo activationT cell stimulation

Identifiers

PMID38358310
PMCPMC11161322
OpenAlexW4391845009

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.